factual
Achaogen bankruptcy after plazomicin approval
Achaogen spent years and millions developing the antibiotic plazomicin, which the FDA approved in June 2018 only for urinary tract infections rather than the bloodstream infections the company had bet on; the company filed for bankruptcy nine months later, illustrating why startups now avoid antibiotic development.
factualpending
Speaker
Matt McCarthyEvidence Quote
“the company filed for bankruptcy nine months later”
Created: 6/14/2026, 2:12:29 AM
Your notes
Loading notes...